Scorpius Holdings
Scorpius Holdings Inc., through its subsidiary, is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic programs to the clinic and beyond. It offers analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. The company is dedicated to transparent collaboration and high-quality biologics biomanufacturing with an experienced team and purpose-built U.S. facilities.
Industries
Nr. of Employees
medium (51-250)
Scorpius Holdings
Morrisville, North Carolina, United States, North America
Patents
Services
On-site CDMO services supporting development through clinical manufacturing at U.S.-based facilities for pharmaceutical and biotechnology clients.
Laboratory analytical testing and characterization to support product development, release testing and regulatory submissions for biologic products.
Process development including optimization, scale-up and technology transfer to manufacturing to enable clinical supply readiness.
Collaborative engagements with external cell line development providers to support upstream development activities and integration into manufacturing workflows.
Equity-based venture incubation program to support U.S. biotech innovation and onshoring of development or manufacturing activities through strategic partnerships.
On-site CDMO services supporting development through clinical manufacturing at U.S.-based facilities for pharmaceutical and biotechnology clients.
Laboratory analytical testing and characterization to support product development, release testing and regulatory submissions for biologic products.
Process development including optimization, scale-up and technology transfer to manufacturing to enable clinical supply readiness.
Collaborative engagements with external cell line development providers to support upstream development activities and integration into manufacturing workflows.
Equity-based venture incubation program to support U.S. biotech innovation and onshoring of development or manufacturing activities through strategic partnerships.
Expertise Areas
- Biologics contract development and manufacturing
- Process development and technology transfer for clinical supply
- Analytical characterization and release testing for biologics
- Cell line development and upstream process integration
Key Technologies
- Cell line development and upstream expression systems
- Analytical bioassays and characterization methods
- Bioprocess scale-up and optimization
- Technology transfer workflows
News & Updates
The company announced its third quarter 2024 financial results, emphasizing strategic partnerships, cost savings, and progress toward profitability.
The company announced its third quarter 2024 financial results, emphasizing strategic partnerships, cost savings, and progress toward profitability.